天士力(600535.SH):P134細胞注射液獲得藥物臨牀試驗批準通知書
格隆匯4月11日丨天士力(600535.SH)公佈,公司收到國家藥品監督管理局覈準簽發關於P134細胞注射液用於復發膠質母細胞瘤的《藥物臨牀試驗批準通知書》。P134細胞注射液是由天士力與北京神經外科研究所共同合作開發的創新生物藥,是一款靶向CD44和(或)CD133的自體CAR-T產品,其作用機制爲特異性識別並結合在原發性和複發性膠質母細胞瘤(GBM)中呈現特異性互斥高表達抗原靶標,高效激活並延長T細胞壽命,從而殺傷腫瘤細胞。截至目前,全球範圍內尚無用於復發膠質母細胞瘤適應症的同類產品獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.